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Cisplatin is a potent chemotherapeutic drug widely used for the treatment of human cancer. However, its
efficacy against hepatocellular carcinoma (HCC) is poor for reasons that remain unclear. We show here
that prothymosin-alpha (PTMA) is overexpressed in HCC cell lines. Silencing PTMA using short-hairpin
RNA sensitizes HCC cells to cisplatin, while ectopic expression of PTMA induces cell resistance to the
drug. Cisplatin inhibits both the JNK pathway and PTMA in a dose-dependent manner. Treatment with
a JNK inhibitor also reduces PTMA protein stability and sensitizes HCC cells to cisplatin. Notably, the
effects of PTMA silencing and JNK inhibition can be reversed by ectopic expression of PTMA. We show
that PTMA silencing induces translocation of proapoptotic Bax to mitochondria and enhances cisplatin-
induced cytochrome c release and caspase-9 activation. Conversely, ectopic expression of PTMA reverses
these effects. Our results indicate that PTMA is positively regulated by JNK and protects HCC cells against
cisplatin-induced cell death. The JNK/PTMA axis may thus represent a novel target for chemotherapy
against HCC.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is a complex liver disease asso-
ciated with high mortality and prevalence worldwide [1]. HCC
patients often respond poorly to current clinical treatments,
including chemotherapy. Poor prognosis and high mortality rates
are attributed in part to the difficulty in obtaining a diagnosis at
an early stage. Alterations, up-regulations, and mutations in vari-
ous genes and cellular signaling pathways have been shown to pro-
mote hepatocarcinogenesis and protect cancer cells against clinicaltreatment. We showed earlier that two anti-apoptotic proteins that
are upregulated in human HCC [2,3]—HURP (hepatoma upregu-
lated protein) and PTMA (prothymosin-a) [4,5]—represent impor-
tant targets of sorafenib in HCC cells cultured in vitro [6,7].
PTMA has been described as a ‘‘thymic hormone” that may be
used as a tumor biomarker and to trigger anticancer immune
responses [8]. Recent evidence suggests that PTMAmay play differ-
ent roles depending on the cellular context. In the cell, PTMA con-
trols the cell cycle, whereas in the extracellular space, this protein
exerts immunomodulatory effects. PTMA expression and localiza-
tion varies during hepatocyte proliferation and apoptosis in rat
hepatocytes [9]. This protein was found to be highly expressed in
human HCC [5]. In addition, high levels of PTMA and c-Myc were
detected in various human tumors, including HCC [10–12]. c-Myc
upregulates PTMA transcription [13], and c-Myc-binding sites
were identified in both the proximal promoter and intron 1 of
the PTMA gene [14–16]. We recently found that PTMA overexpres-
sion is negatively correlated with sorafenib sensitivity in HCC cells.
The role of PTMA in the development of human HCC may involve
regulation of PTMA at the transcriptional level by c-Myc [7]. In
addition, we identified a sorafenib-responsive element in the
PTMA promoter, and demonstrated that sorafenib inhibits PTMA
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catenin/JNK pathway [6].
The mechanism underlying regulation of PTMA expression and
the possibility that this protein may produce anti-apoptotic effects
in HCC cells exposed to chemotherapy have not been investigated.
Activation of mitogen-activated protein kinases (MAPKs) is
believed to be a major factor in determining the fate of cancer cells
in response to cisplatin. The role of MAPKs in response to cisplatin
is complex as these proteins are able to induce apoptosis, but,
depending on the cell type, may also suppress this process or be
involved in other cellular pathways such as cell proliferation and
differentiation [17]. As a member of the MAPK family, JNK modu-
lates the activity of numerous proteins locating in the mitochon-
dria and the nucleus in response to cisplatin treatment, and also
plays a major role in determining the fate of human tumors. The
JNK signal pathway has been suggested to represent a double-
edged sword in response to cisplatin, being a significant pro-
apoptosis factor but also being associated with increased resis-
tance to the drug [18]. We recently demonstrated that the JNK
pathway plays a critical role in inhibition of PTMA by sorafenib
[7]. However, the relationships between cisplatin, JNK signaling
and PTMA remain to be characterized in more details. In the pre-
sent study, we show that PTMA is positively regulated by JNK
and protects HCC cells against cell death induced by the
chemotherapeutic drug cisplatin. The JNK/PTMA axis may thus
represent a novel target for HCC treatment.2. Materials and methods
2.1. Cell culture and reagents
Hepatocellular carcinoma cells (Huh7, J7, SK-Hep1, and Mah-
lavu) were obtained from the American Cell Type Collection (ATCC;
Manassas, VA, USA). Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Gaithersburg, MD, USA) supple-
mented with 10% (v/v) fetal bovine serum (FBS), penicillin (100
U/ml; Gibco), and streptomycin (100 mg/ml; Gibco). Cells were
cultured at 37 C in a humidified atmosphere of 5% CO2 (v/v) in
air. Commercial antibodies that react against Bad, Bid, pJNK, pAKT,
AKT (Cell Signaling, Danvers, MA, USA), PTMA, survivin, Mcl-1, Bcl-
XL, Bcl-2, Bax, Bim, GAPDH, VDAC, JNK, pP38, P38, pERK, ERK, and
IjB-a (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used
according to guidelines provided by the manufacturer. Chemical
inhibitors against NF-jB (Bay11-7082), JNK (SP600125), P38
(SB203580) (Santa Cruz Biotechnology), MEK/ERK (U0126) (Cal-
biochem, Billerica, MA, USA), and PI3K (Wortmannin; Cell Signal-
ing) were also used.
2.2. Plasmids and cell transfection
The pcDNA3 plasmid was used as a negative control. pcDNA3-
PTMA was constructed as previously described [7]. Plasmid con-
struction and preparation was performed according to standard
procedures [19]. HCC cells were transfected with plasmids using
Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the
instructions provided by the supplier. Transfected cells were incu-
bated 48 h for overexpression of the plasmids.
2.3. Quantitative real-time reverse transcription-PCR (qRT-PCR)
qRT-PCR, or in short qPCR, was performed on total RNA
extracted with Trizol (Invitrogen) and 200 nM of primers as before
[20]. The primers used were as follows: PTMA, forward, 50-CGAAAT
CACCACCAAGGACT-30; reverse, 50-GTCGGTCTTCTGCTTCTTGG-30;
and GAPDH, forward, 50-TCCTGCACCACCAACTGCTT-30; reverse, 50-GAGGGGGCCATCCACGTCTT-30. All samples and controls were
prepared in triplicate. Relative quantification was calculated using
theDDCt method and normalized against GAPDH as described ear-
lier [21]. Namely, DCt was calculated as DCt (candidate) = [Ct (can-
didate)  Ct (GAPDH)]. Relative abundance of the candidate gene X
was shown as 2DCt(X)–DCt(GAPDH).
2.4. Western blot analysis
Whole cell protein extracts were prepared for immunoblotting
as before [22]. Protein concentration was determined using the
Bradford assay and the BioRad dye reagent (BioRad, Hercules, CA,
USA). Proteins (50 lg) from each sample were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred onto PVDF membranes, prior to incubation with anti-
bodies according to the instructions of the manufacturer. Protein
signals were revealed using enhanced chemiluminescence accord-
ing to specifications of the supplier (Pierce, Rockford, IL, USA). Pro-
tein band intensity was quantified using a scanning densitometer
(Personal Densitometer SI; Amersham Biosciences, Sunnyvale, CA,
USA).
2.5. Gene silencing using short-hairpin RNA
pLKO.1 plasmid expressing shRNA to silence PTMA
(TRCN0000135421) was purchased from the National RNAi Core
Facility (Taipei, Taiwan). Luciferase shRNA (TRCN0000072244)
was used as a negative control. Unless indicated otherwise, tran-
sient transfection was performed by adding 2 lg/well of shRNA
plasmid along with 5 ll/well of Lipofectamine into cell suspen-
sions kept in six-well plates (1.5  104 cells/well) as described ear-
lier [21]. Stable clones expressing shRNA plasmids via lentivirus as
vector were established in HCC cells.
2.6. Preparation of mitochondria and cytosol fractions
Cells were washed once with PBS, prior to lysis in 3.5 mM Tris-
HCl, 2 mM NaCl, 0.5 mMMgCl2 using a homogenizer with a motor-
driven Teflon pestle. Cell homogenates were immediately mixed
with nine volumes of 0.35 M Tris-HCl, 0.2 M NaCl, 50 mM MgCl2,
and centrifuged for 3 min at 1600 g to pellet unbroken cells, debris,
and cell nuclei. The supernatant was centrifuged under the same
conditions. The final supernatant was partitioned in tubes and cen-
trifuged at 13,000g for 5 min. The supernatant (cytosolic protein)
was collected. Mitochondrial pellets were washed once with
35 mM Tris-HCl, 20 mM NaCl, 5 mM MgCl2, prior to resuspension
in lysis buffer (1 PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, and protease inhibitor cocktail; BD Biosciences, San Jose, CA,
USA) and incubation for 15 min. The entire purification process
was performed at 4 C.
2.7. Analysis of cell viability and apoptosis
Cells were treated with cisplatin in culture medium for three
days unless indicated otherwise. Cell viability was determined
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) colorimetric assay [23]. Percentage of viable cells
was calculated as the ratio of OD570nm values of treated cells
divided by the OD570nm values of control cells. To evaluate apopto-
sis, sub-G1 cells were quantified as before [24]. Stained nuclei were
analyzed using the BD FACScan Flow Cytometer (Becton & Dickin-
son, San Jose, CA, USA) with 10,000 events/determination. The
LYSYS II software was used to assess cell cycle distribution. Unless
indicated otherwise, samples were prepared in quadruplicate and
three independent experiments were performed.
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Data were reported as means ± standard deviation (SD). Three
independent experiments were performed unless indicated other-
wise. Statistical significance (p value) was calculated with a two-
tailed Student’s t test for single comparison. The symbols *, **,
and *** denote p < 0.05, p < 0.01 and p < 0.001, respectively.Fig. 1. PTMA silencing down-regulates PTMA, up-regulates Bax, and enhances cisplatin-i
severely down-regulated by cisplatin in HCC cell lines. While Bcl-2, Bcl-XL, and Mcl-1 w
Quantified PTMA protein ratio is shown in the lower panel. (B) Bax apoptotic protein is
lower panel. (C) Enhancement of cisplatin-induced caspase-9, caspase-3 and PARP cleav
shLuc plasmids via the lentivirus vector were treated with the indicated concentrations
experiments to detect caspase-9, caspase-3 and full-length PARP (FL PARP) as well as clea
PTMA silencing. Fifty lg of total protein extract was used for immunoblotting with the
following PTMA silencing. Cell sensitivity was assessed using the MTT assay. IC50 (the con
are shown. SF50 was calculated by dividing the IC50 of control shLuc cells by that of shPTM
*P < 0.05, **P < 0.01, and ***P < 0.001.3. Results
3.1. PTMA silencing sensitizes HCC cell lines to cisplatin-induced
apoptosis
To assess the role of PTMA in cisplatin-treated HCC cells, we
exposed HCC cell lines (Huh7, SK-Hep1, Mahlavu, and J7) to a
lethal concentration of cisplatin (10 lM) and examined the levelnduced apoptosis and cell death in HCC cells. (A) The antiapoptotic protein PTMA is
ere not affected, survivin protein levels increased in HCC cells exposed to cisplatin.
moderately up-regulated by cisplatin. Quantified Bax protein ratio is shown in the
age following PTMA knockdown. Mahlavu cells stably expressing either shPTMA or
of cisplatin for 24 h. Fifty lg of total protein extract was used in immunoblotting
ved PARP. (D) Enhancement of cisplatin-induced sub-G1 cell accumulation following
antibodies shown in Fig. 1A, B and C. (E) Sensitization of Mahlavu cells to cisplatin
centration of cisplatin that inhibits 50% of cell growth) and sensitization factor (SF50)
A cells. Results are expressed as means ± SD for experiments performed in triplicate.
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(Fig. 1B) using Western blot analysis. While PTMA protein levels
were reduced following treatment with cisplatin, the level of Bax
increased in these cells. Compared with the shLuc control, silencing
of PTMA using shRNA enhanced cisplatin-induced activation of
caspase-3 and 9 and cleavage of the PARP substrate in Mahlavu
cells, which express abundant PTMA (Fig. 1C). Flow cytometry
analysis showed that apoptotic, sub-G1 Mahlavu cells increased
in a time-dependent manner and concentration-dependent man-
ner following treatment with cisplatin (Fig. 1D). Notably, PTMA
silencing further increased cisplatin-induced accumulation of
sub-G1 cells (Fig. 1D). In the MTT cell viability assay, PTMA silenc-Fig. 2. Ectopic expression of PTMA protects HCC cells against cisplatin. (A) Reduction of c
or control GFP were treated with cisplatin (10 or 20 lM) for 24 h, and cell extracts were i
plasmids were used to express PTMA and control proteins, respectively. Endogenous PTM
the immunoblots using the indicated antibodies. (B, D) Reduction of cisplatin-induced s
resistance to cisplatin in J7 and SK-Hep1 cells overexpressing PTMA. Calculated resistan
cells by that of control GFP cells. Results shown in (B–E) are expressed as means ± SD foing also enhanced cisplatin-induced cell death, producing a sensi-
tization factor (SF50) of 1.71 (Fig. 1E; SF50 = IC50 shLuc/IC50
shPTMA). These results indicate that PTMA silencing enhances
cisplatin-induced apoptosis and cell death in HCC cells.
3.2. Ectopic expression of PTMA protects cells against cisplatin-induced
apoptosis
Compared with GFP overexpression used as control, overex-
pression of FlagPTMA (a PTMA fusion protein containing the Flag
tag) reduced cisplatin-induced activation of caspase-3 and -9,
and cleavage of PARP in J7 and SK-Hep1 cell lines, which bothaspase activity by overexpression of PTMA. J7 or SK-Hep1 cells expressing FlagPTMA
mmunoblotted with antibodies for the indicated proteins. FlagPTMA fusion and GFP
A and exogenous FlagPTMA are shown. Fifty lg of total protein extract was used for
ub-G1 cells by PTMA overexpression in HCC J7 and SK-Hep1 cells. (C, E) Increased
t factors (RF50) are indicated. RF50 was calculated by dividing the IC50 of FlagPTMA
r experiments performed in triplicate. Symbols are the same as in Fig. 1.
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G1 cells increased in a dose-dependent manner following treat-
ment with cisplatin, FlagPTMA overexpression significantly
reduced sub-G1 cell accumulation (Fig. 2B). Reduction of
cisplatin-induced cell viability was reversed by FlagPTMA overex-
pression in J7 cells, producing a resistance factor (RF50) of 3.38
(Fig. 2C; RF50 = IC50 Flag PTMA/IC50 GFP). Similarly, the effects of
cisplatin on sub-G1 cells and cell viability were reversed by
FlagPTMA overexpression in SK-Hep1 cells (Fig. 2D and E).3.3. Cisplatin enhances PTMA protein degradation via inhibition of JNK
To assess the mechanism underlying the down-regulation of
PTMA by cisplatin, we monitored protein stability in Mahlavu cells
pre-treated with cycloheximide, an inhibitor of translation initia-
tion. PTMA protein degradation rate was enhanced by cisplatin
treatment, producing a regression slope of 0.93 for cisplatin-
treated cells vs. 0.56 for control PBS-treated cells
(Fig. 3A and B). In contrast, steady-state PTMA mRNA levels were
not affected by cisplatin treatment (Fig. 3C). In fact, mRNA degra-
dation rate was only slightly reduced in cells preteated with acti-
nomycin D, an inhibitor of mRNA synthesis, and incubated in
media containing cisplatin (Fig. 3D, slope of 3.343 for cisplatin-
treated cells vs. 4.800 for PBS-treated cells).
To determine the signaling pathway involved in PTMA protein
degradation, we examined the kinase pathways affected by cis-
platin in Mahlavu cells. Antibodies that react against phosphory-
lated kinases were used to assess kinase activation. While several
kinases such as NFjB (IjB-a), P38, ERK and AKT were unaffected
or their level of phosphorylation increased following treatmentFig. 3. Cisplatin attenuate PTMA expression through protein degradation. (A) Suppressio
cycloheximide (CHX), an inhibitor of protein synthesis, followed by the indicated incubat
cisplatin-treated Mahlavu cells. Protein level was normalized to GADPH. Linear regression
mRNA expression by cisplatin. PTMA mRNA level was evaluated by qPCR. The difference i
experiments performed in triplicate. *P < 0.05, **P < 0.01. (D) Slight reduction in the de
incubated with actinomysin D (Act. D), an inhibitor of RNA synthesis, followed by the in
PTMA mRNA level.with cisplatin, JNK was transiently inhibited by the drug (Fig. 4A).
Treatment with kinase inhibitors revealed that PTMA protein levels
were inhibited by JNK, MEK/ERK, and PI3K inhibitors (Fig. 4B).
These results suggest that the down-regulation of PTMA observed
in cisplatin-treated HCC cells may occur via inhibition of the JNK
pathway. To confirm the functional role of JNK, we treated Mah-
lavu cells with the JNK inhibitor and observed that PTMA protein
degradation was indeed induced in the presence of cycloheximide
(Fig. 4C and D).3.4. Ectopic expression of PTMA rescues the effects of JNK inhibitor on
cisplatin sensitivity
The significance of the JNK pathway in regulating cisplatin sen-
sitivity was examined using the MTT cell viability assay. While JNK
inhibition sensitized Mahlavu cells to cisplatin compared to con-
trol DMSO (Fig. 4E, SF50 = 1.56), ectopic expression of PTMA
restored cell viability, producing a RF50 of 2.40 (Fig. 4E). Inhibition
of JNK activity by cisplatin (Fig. 4F) and reduction of PTMA protein
level by JNKi (Fig. 4G) were observed in Huh7 cells. Sensitization of
Huh7 cells to cisplatin by JNKi could be restored by PTMA overex-
pression (Fig. 4H, RF50 = 3.75). Similarly, inhibition of JNK activity
by cisplatin (Fig. 4I) and PTMA protein levels by JNKi (Fig. 4J) were
observed in J7 cells. Sensitization of J7 cells to cisplatin by JNKi was
also restored by PTMA overexpression (Fig. 4K, RF50 = 4.44). Exoge-
nous expression of FlagPTMA as well as endogenous PTMA protein
level is shown in Fig. 4L. These results show that JNK mediates
cisplatin-induced PTMA down-regulation and that ectopic expres-
sion of PTMA rescues the effects of JNK inhibition on HCC cell sen-
sitivity to cisplatin.n of PTMA protein expression by cisplatin. Mahlavu cells were pre-incubated with
ion in cisplatin-containing media. (B) Increased degradation rate of PTMA protein in
of the kinetic pattern of PTMA protein level is shown. (C) Lack of inhibition of PTMA
n mRNA level was compared to PBS control. Results are expressed as means ± SD for
gradation rate of PTMA mRNA in cisplatin-treated Mahlavu cells. Cells were pre-
dicated incubation. Results are shown as linear regression of the kinetic pattern of
Fig. 4. Downregulation of PTMA by cisplatin is mediated by the JNK signaling pathway. (A) Transient decrease of JNK signaling in cisplatin-treated Mahlavu cells. Cells were
treated with cisplatin (10 lM) for the indicated time. NF-jB activity is shown by the level of its inhibitor I-jB. Fold change of phosphorylated kinase is calculated after
normalization to total kinase. (B) Reduction of PTMA protein level by JNK, MEK/ERK, and PI3K inhibitors in Mahlavu cells. Cells were treated with the indicated concentrations
of inhibitors (see Materials and methods) for 4 h. Identification of kinase pathway by using specific kinase inhibitors, including NF-jBi (Bay11-7082), JNKi (SP600125), p38i
(SB203580), ERKi (U0126), and PI3Ki (Wortmannin). DMSO, used to dissolve the inhibitors, was used as control. Relative protein level (each lane was first normalized to
GADPH) was calculated against the DMSO control (lane 1). (C) Suppression of PTMA protein expression by JNK inhibitor (JNKi). Mahlavu cells were pre-incubated with
cycloheximide (CHX), followed by the indicated incubation in JNKi-containing media. (D) Increased degradation rate of PTMA protein in JNKi-treated Mahlavu cells. Linear
regression of the kinetic pattern of PTMA protein level is indicated. (E) Sensitization of Mahlavu cells to cisplatin by JNKi treatment and reversal by PTMA overexpression. Cell
viability was assessed using the MTT assay. Differences are calculated as averages of three experiments. Sensitization factor (SF50) and resistance factors (RF50) are shown.
Symbols are the same as in Fig. 1. (F) Decrease of JNK signaling in cisplatin-treated Huh7 cells. (G) Reduction of PTMA protein level by JNK, p38, MEK/ERK, and PI3K inhibitors
in Huh7 cells. (H) Sensitization of Huh7 cells to cisplatin by JNKi treatment and reversal by PTMA overexpression. Symbols are the same as for panel E. (I) Decrease of JNK
signaling in cisplatin-treated J7 cells. (J) Reduction of PTMA protein level by JNK, MEK/ERK, and PI3K inhibitors in J7 cells. (K) Sensitization of J7 cells to cisplatin by JNKi
treatment and reversal by PTMA overexpression. (L) Expression of endogenous and exogenous PTMA in Mahlavu, J7, and Huh7 cells. These data are references for the cell
viability experiments (panels E, H and K). The results shown are expressed as means ± SD for experiments performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
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86 Y.-T. Lin et al. / Biochemical Pharmacology 122 (2016) 80–893.5. Ptma silencing enhances translocation of proapoptotic Bax to
mitochondria, and cisplatin-induced cytochrome c release and
caspase-9 activation
To assess the effects of PTMA on cisplatin-induced apoptosis,
we examined the expression of anti-apoptotic and pro-apoptotic
proteins in Mahlavu cells following PTMA silencing. While the
steady-state level of survivin and Bcl-XL increased in cisplatin-
treated cells, Mcl-1 and Bcl-2 protein levels were only moderately
reduced (Fig. 5A, lanes 1–3). Except for Bcl-XL, the level of these
proteins increased following PTMA silencing (Fig. 5A, compare
lanes 1 and 4). Silencing of PTMA produced only a minor effect
on these anti-apoptotic proteins (Fig. 5A, compare lanes 1–3 with
lanes 4–6). Pro-apoptotic proteins such as Bad and Bax were
induced by cisplatin. Silencing of PTMA only slightly affected
cisplatin-induced regulation of these proteins (Fig. 5A, compareFig. 5. Cisplatin-induced caspase-9 activation is enhanced by PTMA silencing and is asso
Regulation of Bcl-2 and Bax following cisplatin and PTMA silencing in Mahlavu cells. O
Relative protein level (with each lane first normalized to GADPH) was calculated again
mitochondrial release of cytochrome c by shPTMA in Mahlavu cells. Caspase-9 cleavage w
markers, respectively. (C) Quantification of mitochondrial Bax in shPTMA-expressing cell
caspase-9 cleavage in shPTMA-expressing cells. Results are expressed as means ± SD forlanes 1–3 with lanes 4–6). Like most anti-apoptotic proteins, Bax
level approximately doubled following down-regulation of PTMA
in cells not treated with cisplatin. Unexpectedly, cisplatin-
induced mitochondrial translocation of Bax (Fig. 5B, compare lanes
1–3 with lanes 7–9) was enhanced by PTMA silencing (compare
lanes 7–9 with lanes 10–12). Furthermore, cytosolic levels of cyto-
chrome c increased following cisplatin treatment (Fig. 5B, lanes 1–
3). On the other hand, release of cytochrome c from mitochondria
was enhanced by PTMA silencing (Fig. 5B, compare lanes 1–3 with
lanes 4–6). In addition, cisplatin-induced cleavage of caspase-9
was enhanced by PTMA silencing. Thus, induction of cisplatin-
induced apoptotic signals following PTMA silencing includes mito-
chondrial translocation of Bax (Fig. 5C), cytochrome c release from
mitochondria (Fig. 5D), and activation of caspase-9 (Fig. 5E). It has
been well documented that caspase-9 activation is dependent on
Bax associated cytochrome c release from mitochondria [25]. Weciated with expression and mitochondrial translocation of Bax in Mahlavu cells. (A)
ther apoptotic regulators (survivin, Mcl-1, Bcl-XL) were not affected by shPTMA.
st shLuc control (lane 1). (B) Increase in mitochondrial Bax and cisplatin-induced
as enhanced by shPTMA. a-Tubulin and VDAC are used as cytosol and mitochondria
s. (D) Quantification of cytosolic cytochrome c in shPTMA cells. (E) Quantification of
experiments performed in triplicate. *P < 0.05, **P < 0.01.
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this process plays a critical role in inducing caspase-9 activation
in Mahlavu cells.3.6. Ectopic expression of PTMA inhibits Bax translocation to
mitochondria and induces cytochrome c release and caspase-9
activation
To confirm the role of PTMA in regulating apoptosis, we per-
formed similar experiments in J7 cells which express minimal
amount of PTMA. While Bcl-2 protein level was induced by PTMA
overexpression, other anti-apoptotic proteins were not affected by
PTMA overexpression (Fig. 6A, compare lanes 1–3 with lanes 4–6).
Cisplatin-induced Bad and Bax protein levels remained unchanged
following FlagPTMA overexpression compared to GFP control.
Conversely, cisplatin-induced mitochondrial translocation of BaxFig. 6. Cisplatin-induced caspase-9 activation is down-regulated by ectopic expressi
overexpression (FlagPTMA) in J7 cells. (B) Reduction of cisplatin-induced mitochondrial
PTMA overexpression (FlagPTMA). (C) Quantification of mitochondrial Bax in FlagPTMA-e
expressing cells. (E) Quantification of caspase-9 in FlagPTMA-expressing cells. Results areprotein was reduced by ectopic expression of PTMA (Fig. 6B, com-
pare lanes 7–9 with lanes 10–12). Furthermore, cisplatin-induced
cytosolic cytochrome c level and caspase-9 activation were
reduced by PTMA overexpression in these cells (Fig. 6B). Quantifi-
cation of the apoptotic proteins is shown in Fig. 6CE. Taken
together, our results demonstrate that PTMA plays an important
role in regulating cisplatin-induced apoptosis in HCC cells via path-
ways that have not previously described.4. Discussion
Using loss-of-function and gain-of-function assays, we report
here that PTMA plays a key role in regulating cisplatin sensitivity
in HCC cells. Overexpression and silencing of PTMA respectively
protects and sensitizes HCC cell lines to cisplatin, supporting the
concept that PTMA represents an anti-apoptotic protein [7].on of PTMA in J7 cells. (A) Reduction of Bax and induction of Bcl-2 by PTMA
localization of Bax and cisplatin-induced mitochondrial release of cytochrome c by
xpressing cells. (D) Quantification of decreased cytosolic cytochrome c in FlagPTMA-
expressed as mean ± SD for experiments performed in triplicate. *P < 0.05, **P < 0.01.
Fig. 7. Model illustrating the signaling pathways and the role of PTMA in cisplatin-
induced apoptosis in HCC cells. PTMA is involved in the regulation of cisplatin-
induced apoptosis through two pathways, including (1) PTMA degradation induced
by cisplatin through inhibition of the JNK pathway, and (2) potentiation of
mitochondrial translocation of pro-apoptotic proteins (Bax) and subsequent release
of cytochrome c from mitochondria. PTMA plays a protective role in this context.
Also included here is the direct effect of PTMA on apoptosome assembly (3) which
was described previously [36,37]. This novel model explains at least in part the
caspase 9-dependent apoptosis induced by cisplatin in HCC cells.
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most consistently down-regulated protein in HCC cells treated
with a cytotoxic concentration of cisplatin. However, unlike sorafe-
nib for which a significant correlation has been observed between
the IC50 produced by the drug and PTMA level observed in HCC cell
lines [6], the correlation between the IC50 of cisplatin and PTMA
level observed in the present study is relatively low. Nevertheless,
our results suggest that PTMA clearly regulates cisplatin sensitivity
in isogenic HCC cells. The contribution of other known anti-
apoptotic proteins in regulating cisplatin sensitivity appears to
be minimal since their expression levels were not affected by cis-
platin in the HCC cell lines studied here (see Fig. 1). Clinical evi-
dence also indicates that PTMA represents an important marker
that may help to predict therapy outcome. A recent study which
examined immunohistochemistry of tumor tissues from 226 HCC
patients who underwent curative hepatectomy showed that PTMA
protein expression may represent a novel predictor of early recur-
rence and recurrence-free survival in HCC patients [26].
The level of apoptotic Bax was also induced by cisplatin in all
HCC cell lines tested in the present study (Fig. 1). Other known
apoptotic proteins (Bad, Bim, and Bid) were not affected by cis-
platin in these cells. Mitochondrial translation of Bax was
enhanced by PTMA silencing in Mahlavu cells which constitutively
express a high level of this protein. In contrast, ectopic expression
of PTMA in J7 cells, which express relatively low PTMA protein
level, reduced the mitochondrial fraction of Bax protein (Fig. 5).
These results suggest that the overall level of apoptotic Bax protein
and its mitochondrial fraction are upregulated by cisplatin. The
change in Bax level and cellular location in HCC cells in response
to cisplatin stress correlates with cytochrome c release from mito-
chondria and apoptosome activation (caspase-9). Activation of
downstream caspase-3, apoptotic sub-G1 cells and cell growth
inhibition by cisplatin was also enhanced by PTMA silencing, while
PTMA overexpression reversed these cellular processes (see Figs. 1
and 2). To our knowledge, we demonstrate for the first time the
functional role of PTMA in regulating Bax and caspase-dependent
apoptosis.
In this study, we found that inhibition of JNK, MEK and PI3K by
specific kinase inhibitors consistently down-regulated PTMA
expression in HCC cell lines (Mahlavu, Huh7, and J7). Only the
JNK signal was inhibited by cisplatin in these cells (see Fig. 4), sug-
gesting that cisplatin may inhibit PTMA via the JNK pathway. We
also observed that PTMA protein degradation was faster following
treatment with either cisplatin or the JNK inhibitor compared to
control. However, the level of PTMA mRNA was not affected by
these treatments (Figs. 3 and 4). These results indicate that PTMA
regulates cisplatin-induced apoptosis in HCC cells by regulating
JNK at the post-translational level. We have previously described
the cellular mechanism in which sorafenib targets PTMA gene
transcription by inhibiting ERK kinase-regulated Myc/Max and b-
catenin-regulated JNK/AP-1/TCF4 in HCC cells [6,7]. Like sorafenib,
cisplatin down-regulates PTMA expression in HCC cells. Unlike sor-
afenib, however, cisplatin down-regulates PTMA expression in a
post-translational manner via the JNK pathway (see the model pre-
sented in Fig. 7).
In the present study, we also examined the possible involve-
ment of PTMA reduction by cisplatin, which led to enhanced mito-
chondrial translocation of pro-apoptotic Bax (Fig. 7). The same
cellular response was observed earlier in HCC cells in response to
sorafenib [7], indicating that this cellular response may be critical
to both treatments. Using cell viability assay, we observed that
PTMA silencing produces a SF50 of 1.71 in response to cisplatin
while sorafenib produces a SF50 of 1.51 [7]. In our experiments,
both drugs produced similar effects in cultured HCC cells when
used within the micromolar concentration range, suggesting that
a combination of either drug and PTMA silencing may show similarefficacy in inhibiting HCC cell growth. The mechanism identified
for cisplatin-induced apoptosis is also responsible for the activities
of other platinum-containing anti-cancer agents, such as carbo-
platin, which is also used in cancer treatment (data not shown).
Our finding that the PTMA/JNK signaling pathway is involved in
response to cisplatin is likely to have clinical implications.
Sorafenib was described as a multi-kinase inhibitor that target
various pathways including RAF/MEK/ERK, vascular endothelial
growth factor receptor (VEGFR), platelet derived growth factor
receptor (PDGFR)-b, KIT, FLT-3, RET and Wnt/b-catenin [27–29].
Cellular signaling of the Raf-1 and vascular endothelial growth fac-
tor (VEGF) pathways has been implicated in HCC pathogenesis
[30–33], thereby providing a rationale for the clinical use of sora-
fenib. However, limited survival benefits have been observed since
sorafenib has been used as a standard therapy for advanced HCC
[34,35]. Our results indicate that targeting or silencing PTMA
may enhance the effects of cisplatin and sorafenib in HCC. The
PTMA-based response of HCC cells to cisplatin appears to be simi-
lar to that of sorafenib, which may lead to the potential use of cis-
platin in advanced HCC. However, the microenvironment of HCC
should be taken into account while evaluating the efficacy of these
drugs in clinical settings.
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